Literature DB >> 22723617

Extended replacement of the thoracic aorta.

Yutaka Hino1, Kenji Okada, Takanori Oka, Takeshi Inoue, Akiko Tanaka, Atsushi Omura, Hiroya Kano, Yutaka Okita.   

Abstract

OBJECTIVES: We present our experience of total aortic arch replacement.
METHODS: Twenty-nine patients (21 males and 8 females; mean age 63.3 ± 13.3 years) with extended thoracic aortic aneurysms underwent graft replacement. The pathology of the diseased aorta was non-dissecting aneurysm in 11 patients, including one aortitis and aortic dissection in 18 patients (acute type A: one, chronic type A: 11, chronic type B: six). Five patients had Marfan syndrome. In their previous operation, two patients had undergone the Bentall procedure, three had endovascular stenting, one had aortic root replacement with valve sparing and 12 had hemi-arch replacement for acute type A dissection. Approaches to the aneurysm were as follows: posterolateral thoracotomy with rib-cross incision in 16, posterolateral thoracotomy extended to the retroperitoneal abdominal aorta in seven, mid-sternotomy and left pleurotomy in three, anterolateral thoracotomy with partial lower sternotomy in two and clam-shell incision in one patient. Extension of aortic replacement was performed from the aortic root to the descending aorta in 4, from the ascending aorta to the descending aorta in 17 and from the ascending to the abdominal aorta in eight patients. Arterial inflow for cardiopulmonary bypass consisted of the femoral artery in 15 patients, ascending aorta and femoral artery in seven, descending or abdominal aorta in five and ascending aorta in two. Venous drainage site was the femoral vein in 10, pulmonary artery in eight, right atrium in five, femoral artery with right atrium/pulmonary artery in four and pulmonary artery with right atrium in two patients.
RESULTS: The operative mortality, 30-day mortality and hospital mortality was one (cardiac arrest due to aneurysm rupture), one (rupture of infected aneurysm) and one (brain contusion), respectively. Late mortality occurred in three patients due to pneumonia, ruptured residual aneurysm and intracranial bleeding. Actuarial survival at 5 years after the operations was 80.6 ± 9.0%. Freedom from the subsequent aortic events was 96.0 ± 3.9% at 5 years.
CONCLUSIONS: Our treatment method for extensive thoracic aneurysms achieved satisfactory results using specific strategies and appropriate organ protection according to the aneurysm extension in the selected patients.

Entities:  

Mesh:

Year:  2012        PMID: 22723617     DOI: 10.1093/ejcts/ezs200

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

Review 1.  Postoperative imaging of the aorta.

Authors:  Weier Li; Sasiprapa Rongthong; Anand M Prabhakar; Sandeep Hedgire
Journal:  Cardiovasc Diagn Ther       Date:  2018-04

Review 2.  Treatment of post-thoracic endovascular aortic repair aorto-esophageal fistula-only radical surgery can be effective: techniques and sequence of treatment.

Authors:  Drosos Kotelis; Alexander Gombert; Michael J Jacobs
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  Selective Cerebral Perfusion with the Open Proximal Technique during Descending Thoracic or Thoracoabdominal Aortic Repair: An Option of Choice to Reduce Neurologic Complications.

Authors:  Katsuhiro Hosoyama; Shunsuke Kawamoto; Kiichiro Kumagai; Masatoshi Akiyama; Osamu Adachi; Satoshi Kawatsu; Yoshikatsu Saiki
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-01-26       Impact factor: 1.520

4.  One-stage repair of extensive aortic aneurysms: mid-term results with total or subtotal aortic replacement.

Authors:  Xiao-gang Sun; Liang Zhang; Cun-tao Yu; Xiang-yang Qian; Qian Chang
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-11-21

Review 5.  Overview of current surgical strategies for aortic disease in patients with Marfan syndrome.

Authors:  Shunsuke Miyahara; Yutaka Okita
Journal:  Surg Today       Date:  2015-11-19       Impact factor: 2.549

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.